The recent findings from the phase 3 innovaTV trial present significant advancements in the treatment of metastatic and recurrent cervical cancer. Tisotumab vedotin has emerged as a promising candidate to establish a new standard of care for patients who have experienced disease progression after initial chemotherapy.
Key Findings of the innovaTV Trial
The interim analysis revealed that patients treated with tisotumab vedotin-tftv (Tivdak) demonstrated notably improved survival outcomes compared to those receiving standard chemotherapy. Conducted as part of the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial, these results were presented at the 2023 European Society for Medical Oncology Congress.
At a median follow-up of 10.8 months, the median overall survival (OS) for patients receiving tisotumab vedotin was recorded at 11.5 months, as opposed to 9.5 months for those on chemotherapy. The hazard ratio (HR) of 0.70 indicates a significant reduction in the risk of death for those receiving the new treatment. Additionally, the 12-month OS rates were 48.7% for tisotumab vedotin compared to 35.3% for chemotherapy.
Progression-Free Survival Improvements
The trial also demonstrated a marked improvement in progression-free survival (PFS). Patients undergoing treatment with tisotumab vedotin exhibited a median PFS of 4.2 months, compared to just 2.9 months for chemotherapy patients. The HR of 0.67 highlights the efficacy of tisotumab vedotin in slowing disease progression.
Study lead Ignace B. Vergote, MD, PhD, emphasized the potential of tisotumab vedotin to become a new standard of care for patients who have progressed following first-line systemic therapy. Vergote is affiliated with the Leuven Cancer Institute and serves as head of the Department of Obstetrics and Gynecology and Gynecologic Oncology at the Catholic University of Leuven in Belgium.
Addressing a Critical Need
Recurrent or metastatic cervical cancer presents a dire prognosis and significantly high mortality rates, ranking as the fourth deadliest cancer among women globally. While pembrolizumab (Keytruda) has been approved for use in this patient population as a frontline treatment in combination with chemotherapy, additional therapeutic options are urgently needed for those experiencing disease progression.
Tisotumab vedotin operates as an antibody-drug conjugate, combining a human monoclonal antibody that targets tissue factor with the microtubule-disrupting agent MMAE. In 2021, the FDA granted accelerated approval for tisotumab vedotin, based on the results of the single-arm innovaTV 204 trial, where it achieved an objective response rate (ORR) of 24%.
Trial Design and Patient Eligibility
To qualify for the phase 3 innovaTV 301 trial, participants were required to have a documented diagnosis of recurrent or metastatic cervical cancer, with disease progression on or after doublet chemotherapy. Patients were randomly assigned to receive either 2.0 mg/kg of intravenous tisotumab vedotin every three weeks or an investigator’s choice of chemotherapy.
The trial was designed with a sample size of approximately 482 patients, intended to reach a statistical significance level of 0.05. An interim analysis was conducted once 252 OS events were reported, and adjustments were made to the p-value boundaries based on the number of events.
Patient Demographics and Treatment Outcomes
A total of 660 patients were assessed for eligibility, with 502 ultimately randomized into the trial. The demographic characteristics were well-balanced across both treatment arms, ensuring the reliability of the results.
The ORR was significantly higher in the tisotumab vedotin group at 17.8% compared to just 5.2% in the chemotherapy group. The disease control rate also favored tisotumab vedotin, achieving 75.9% versus 58.2% for chemotherapy.
Safety and Tolerability
Tisotumab vedotin was generally well tolerated, with a median relative dose intensity of 96.1% compared to 90.0% for chemotherapy. The occurrence of treatment-related adverse events (TRAEs) was reported in 87.6% of patients receiving tisotumab vedotin, with a notable portion classified as grade 1 or 2. The most common TRAEs included anemia, nausea, and ocular symptoms such as conjunctivitis.
Vergote reassured that the safety profile of tisotumab vedotin was manageable and consistent with prior experiences, indicating its potential for broader clinical application.
Conclusion: A Step Forward in Cervical Cancer Care
The findings from the innovaTV trial present a transformative opportunity for patients with recurrent or metastatic cervical cancer. Tisotumab vedotin not only demonstrates improved survival rates and progression-free survival but also fills a critical gap in treatment options for this vulnerable patient population. As research continues, tisotumab vedotin could redefine the therapeutic landscape for cervical cancer, offering hope and improved outcomes for many.
- Key Takeaways:
- Tisotumab vedotin shows improved overall survival compared to chemotherapy.
- Significant advancements in progression-free survival rates were observed.
- The treatment is well tolerated, with manageable side effects.
- A new standard of care may be established for cervical cancer patients.
Read more → www.cancernetwork.com